Argentine Registry of Crohn's Disease and Ulcerative Colitis (RADECCU)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Aims:
The primary objective of the registry is to create an IBD physicians' network in Argentina that captures pragmatic and relevant information from IBD patients in terms of demographic, clinical and diagnostic aspects. The secondary objective includes safety aspects, including infections, and access to healthcare. The tertiary objective is related to treatment effectiveness. For the treatment effectiveness outcome, information about IBD complications as flares, need of hospitalization and surgery will be included.
Structure of the registry:
The administrative structure of the registry includes an executive committee with an administrative and organizational role which is coordinating with the GADECCU steering committee; a scientific committee that evaluates and coordinates scientific initiatives and promotes specific new strategic projects of interest and approves requests for access to centralized data for research projects. Also, a methodological and regulatory team that provides methodological support to the registry and ensures the regulatory aspects in each institution or region. RADECCU includes a group of technical programmers who develop and provide support to the web platform that allows researchers to register and follow their patients.
Ethical aspects:
The RADECCU registry was approved by the ethics committee of each participant center with a similar project model. Later, individual regulatory and data protection requirements were fulfilled according to all applicable local regulations and laws in each participant center and practice. According the requirements of local approval of each center (need for informed consent or not) the principal investigator or those delegated to the center as co-investigators will fully explains the objective of the registry to all potential participants and encourages their questions. All patients willing to participate in the registry are required to provide an oral or signed consent form (pending on each approval) authorizing release of their coded medical information anonymized to the central registry. To be included in the registry, every center must fulfill the ethical and regulatory conditions.
Population:
Any patient diagnosed with IBD defined by validated diagnostic criteria can be included into the registry. The criteria for IBD diagnosis were agreed with all the members of the Scientific Committee of the registry prior to the start of registration, and were based on previously published criteria for IBD diagnosis, including clinical, endoscopic, laboratory, and histopathological aspects, as well as small bowel imaging studies (Bernstein CN, et al. Inflamm Bowel Dis. 2010;16(1):112-24. doi: 10.1002/ibd.21048.). In order to ensure the inclusion of all IBD patients in Argentina, the executive committee invites all centers associated to GADECCU and involved in the management of IBD patients, regardless of the volume of patients they are in charge of, including both public and private centers. To reduce the possibility of selection bias, each participating physician from each center should aim to include all patients seen in their practice or clinic.
Centers and physicians involved:
Medical assistance to IBD patients in Argentina is mainly provided by several physicians in different institutions and IBD unit throughout the country. The goal of the registry is to include all IBD patients in Argentina and, consequently, all IBD centers and physicians involved in the care of affected patients. All physicians and centers that are part of GADECCU were invited to participate in the registry. In addition, an invitation campaign was carried out at local and national gastroenterology congresses and scientific meetings for physicians not yet linked to GADECCU so that they could get to know and participate in the registry through GADECCU.
The participation in RADECCU is voluntary for both the physicians and the patient. From February-2023 an active promotion of the registry was carried out, resulting in a final incorporation of 65 centers and 138 professionals distributed throughout Argentina.
Data collection and patient confidentiality:
Prevalent and incident cases are included in the Registry by each physician. Once the patient is identified, the requested data is included in a web platform specifically designed for the purpose of the registry. The data is uploaded by the principal investigators of each participating center. The Scientific Committee of RADECCU agree in a prior consensus, on a compulsory common minimum dataset consisting of selected information according to the principles of relevance to ensure the collection of enough data for the clinical characterization of a single patient.
RADECCU is a website with restricted access only to authorized users with a username and password assigned by the executive committee. Users can only view the identifying data of patients they have uploaded themselves, and those who can access the complete database will only have access to an anonymized version of it. The platform will provide data in a comprehensive manner with low cost of development.
During all registration processes, the protection of the patient's identity and data is observed in accordance with the legal regulations in force under the National Law of Protection of Personal Data from Argentina 25.326 (Habeas Data), in accordance with the international legislation on registration of diseases and protection of personal and private data, according to the 18th World Medical Assembly of Helsinki (1964), when applicable. The right to non-participation in the registry is always respected without this implying in any case any type of discrimination, differential treatment or mistreatment towards the patient.
The entire process regarding informed consent, patient evaluation, data entry, data sharing and other procedures of the registry were standardized in an operation procedure described in documents of the registry function, and is available to all researchers in the registry.
Data monitoring:
The structure of the registry was designed considering all the mandatory variables at the time of entry and during the follow-up to be full upload. In this way, data loss is ensured to be kept at a minimum. Data will be centrally monitored by the methodological team to guarantee a high level of quality for the information collected. Centers will be periodically contacted with ad hoc reports with queries on missing data, inconsistencies among variables collected and any duplicates for their resolution.
Research projects:
The mission of RADECCU is not limited to assuring quality healthcare for patients with IBD in Argentina but also to stimulate research projects that address high-priority issues in our region. The philosophy behind the registry takes to reflect the collaborative nature of the project and to encourage epidemiological research efforts in IBD in Argentina. Any researcher who is part of the RADECCU may propose a research project with local or national impact that will be evaluated by the Scientific Committee and, if relevant, will be approved for its development. The data contained in the registry will be used in the research project and, in this way, the performance of various epidemiological studies employing data from RADECCU will also be stimulated.
Statistical analysis plan:
This is an open-ended registry, and sample size is not based on statistical considerations. The main objective of the Registry is a descriptive analysis regarding demographic and clinical aspects, therapy, and safety issues at IBD diagnosis and during follow-up. Statistical analyses will be performed on clinical parameters such as demography, response to therapy and the main aspect of safety, included in the minimum dataset. Analyses may also be performed on other parameters included all the uploaded datasets.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5016
- Recruiting
- Hospital Privado Universitario De Cordoba
-
Contact:
- Domingo C Balderramo, MD, PhD
- Phone Number: +543514688837
- Email: dcbalderramo@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient diagnosed with IBD defined by validated diagnostic criteria can be included into the registry. The criteria for IBD diagnosis were based on previously published criteria for IBD diagnosis, including clinical, endoscopic, laboratory, and histopathological aspects, as well as small bowel imaging studies
Exclusion Criteria:
- Suspected IBD diagnosis without confirmation
- IBD patients with incomplete information about therapy and follow-up
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demography
Time Frame: Observational from July-2023
|
Information from IBD patients in terms of demographic, clinical and diagnostic aspects
|
Observational from July-2023
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety aspects of IBD patients
Time Frame: Observational from July-2023
|
Safety aspects, including infections, and access to healthcare
|
Observational from July-2023
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapy efectiveness
Time Frame: Observational from July-2023
|
For the treatment effectiveness outcome, information about IBD complications as flares, need of hospitalization and surgery will be included
|
Observational from July-2023
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Domingo C Balderramo, MD, PhD, Grupo Argentino de Enfermedad de Crohn y Colitis Ulcerosa
Publications and helpful links
General Publications
- Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinovic A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Gearry R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones GR, Juliao-Banos F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees CW, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Miao Y, Ng KK, Okabayashi S, Olen O, Panaccione R, Paudel MS, Quaresma AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Iade B, Wei SC, Yamamoto-Furusho JK, Yang SK, Ng SC, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025 Jun;642(8067):458-466. doi: 10.1038/s41586-025-08940-0. Epub 2025 Apr 30.
- Mak JWY, Sun Y, Limsrivilai J, Abdullah M, Kaibullayeva J, Balderramo D, Vergara BI, Paudel MS, Banerjee R, Hilmi I, Ali RAR, Wei SC, Ng KK, Altuwaijri M, Kelly P, Yamamoto-Furusho JK, Kotze PG, Ahuja V, Chong VH, Dao HV, Abbey Y, Ching JYL, Ho A, Chan AKW, Bernstein CN, Gearry RB, Abreu M, Rubin DT, Dotan I, Hracs L, Kaplan GG, Ng SC; GIVES-21 Consortium. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 May 25;23(1):129. doi: 10.1186/s12874-023-01944-2.
- Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, Ng SC, Kaplan GG, Kotze PG. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):263-272. doi: 10.1016/S2468-1253(23)00284-4.
- Olivera PA, Balderramo D, Lasa JS, Zubiaurre I, Correa G, Lubrano P, Ruffinengo O, Yantorno M, Rausch A, Pinero G, Bolomo A, Amigo C, El-Hakeh J, Leonardi DB, Brion L, Sambuelli A. Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe inflammatory bowel disease in Argentina: Data from the RISE-AR study. Gastroenterol Hepatol. 2024 Nov 15:502287. doi: 10.1016/j.gastrohep.2024.502287. Online ahead of print. English, Spanish.
- Balderramo D, Trakal J, Herrera Najum P, Vivas M, Gonzalez R, Benavidez A, Lopez Villa D, Daino D, Raiden K, German A, Corzo MA, Ponce de Leon J, Ferrer L, German C, Balzola S, Idoeta A, Zarate F, Defago MR; Grupo Cordoba de Cooperacion para el Manejo y Estudio de la Enfermedad Inflamatoria Intestinal (CEMEI Group). High ulcerative colitis and Crohn's disease ratio in a population-based registry from Cordoba, Argentina. Dig Liver Dis. 2021 Jul;53(7):852-857. doi: 10.1016/j.dld.2021.01.006. Epub 2021 Jan 30.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RADECCU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Therapy
-
NCT04690777CompletedGait | Physical Therapy | Sports Physical Therapy | Exercise Therapy
-
NCT06746428RecruitingGynecologic Cancer | Exercise Therapy | Radiation Therapy
-
NCT03091322CompletedCardiac Resynchronization Therapy | Pacemaker Therapy
-
NCT02918682UnknownFrail Elderly | Exercise Therapy | Physical Therapy Techniques
-
NCT07432139CompletedCognitive Behavioral Therapy | Emotion Focused Therapy
-
NCT04000217CompletedWritten Exposure Therapy | Imaginal Exposure Therapy
-
NCT01387516CompletedCognitive Behavior Therapy | Relaxation Therapy | Motivational Intervention | Nicotine Anonymous
-
NCT05441670Active, not recruitingPhysical Therapy | Hematopoietic Stem Cell Transplantation | Art Therapy
-
NCT06964178CompletedPhotodynamic Therapy | Third Molar Extraction | Antimicrobial Photodynamic Therapy
-
NCT02726802UnknownPhysical Therapy Direct Access | Physical Therapy Primary Care
Clinical Trials on observational study
-
NCT06157723RecruitingKnee Osteoarthritis
-
NCT01836315CompletedObesity | Pregnancy | Cesarean Section
-
NCT03600675Completed
-
NCT02073500RecruitingMesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian Carcinoma
-
NCT02113384Active, not recruiting
-
NCT07664579RecruitingMalignant Solid Neoplasm | Glioblastoma | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Carcinoma | Metastatic Breast Carcinoma
-
NCT07456436RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07439471RecruitingCigarette Smoking-Related Carcinoma
-
NCT07412002RecruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid Neoplasm